Sanofi has launched a phase 3 trial in the EU for one of their combo COVID / Influenza vaccines (Nuvaxovid + FluZone High Dose)

Sanofi has launched a phase 3 trial in the EU of its combination COVID/influenza vaccine, Nuvaxovid + FluZone High Dose, planning to enroll 10,745 participants across 12 countries. The trial is registered as CTIS 2026-526221-18-00, the product has FDA Fast Track designation, and completion is expected on February 10, 2028. No phase 3 trial is yet planned for the Nuvaxovid + Flublok combination.